

SEQ ID NO:1

MTQDCSFQHS PISSDFAVKI RELSDYLLQD YPVTVASNLQ  
DEELCGGLWR LVLAQRWMER LKTVAGSKMQ HFVTKCAFQP  
PPSCLRFVQT NISRLLOETS EQLVALKPWI TRQNFSRCLE  
5 LQCQPDSTL PPPWSPRPLE ATAPTA

## FIGURE 1

---

SEQ ID NO:2

MEGICRNRVT NNVKDVTKLV ANLPKDYMITE LKYVPGMDVL  
PSHCWISEMV VQLSDSLTDL LDKFSNISEG LSNYSIIDKL  
VNIVDDLVEC VKENSSKDLK KSFKSPEPRL FTPEEFFRIF  
NRSIDAFKDF VVASETSDCV VSSTLSPEKD SRVSVTKPFM  
LPPVA

## FIGURE 2

---

SEQ ID NO:3

15 PVPPGEDSKD VAAPHRQPLT SSERIDKQIR YILDGISALR  
KETCNKSNMC ESSKEALAEN NLNLPKMAEK DGCQSGFNE  
ETCLVKIITG LLEFEVYLEY LQNRFESSEE QARAVQMSTK  
VLIQFLQKKA KNLDAITTPD PTTNASLLTK LQAQNQWLQD  
MTTHLILRSF KEFLQSSLRA LRQM

## FIGURE 3

**10**

5

---


107

1000

**FIGURE 5**

40307-36500

A



B





Figure 6


# Surface Marker Characterization Of Rigel's CHMC's



Unstained = Black  
 Isotype Controls = Blue  
 Specific Staining = Red

Figure 7A


# Surface Marker Characterization Of Rigel's CHMC's



Unstained = Black  
 Isotype Controls = Blue  
 Specific Staining = Red

Figure 7B


# Surface Marker Characterization Of Rigel's CHMC's



Unstained = Black  
 Isotype Controls = Blue  
 Specific Staining = Red

Figure 7C

# Stimulation Profile Of Rigel's CHMCs (performed in triplicate)



**Figure 8**

## CD Profile Summary For CHMC's

**A**

### CD15, CD11b, and CD13:

CD15 pos:	3%
CD11b pos:	0%
CD13 pos:	35%
CD15/13 pos:	3%
CD11b/13 pos:	2%
CD11b/15pos:	1%
CD15/13 neg:	55%
CD11b/13 neg:	59%
CD11b/15 neg:	92%

**C**

### CD15, CD11b, and CD14:

CD15 pos:	4%
CD11b pos:	0%
CD14 pos:	39%
CD15/14 pos:	4%
CD11b/14 pos:	2%
CD11b/15pos:	0%
CD15/14 neg:	53%
CD11b/14 neg:	56%
CD11b/15 neg:	91%

**B**

### CD34, CD11b, and CD13:

CD34 pos:	0%
CD11b pos:	0%
CD13 pos:	32%
CD34/13 pos:	1%
CD11b/13 pos:	1%
CD11b/15pos:	0%
CD34/13 neg:	66%
CD11b/13 neg:	66%
CD11b/34 neg:	97%

**D**

### CD34, CD11b, and CD14:

CD34 pos:	0%
CD11b pos:	0%
CD14 pos:	37%
CD34/14 pos:	0%
CD11b/14 pos:	2%
CD11b/34pos:	0%
CD34/14 neg:	58%
CD11b/14 neg:	58%
CD11b/34neg:	96%

**Figure 9**